1. Home
  2. SPRO vs QXL Comparison

SPRO vs QXL Comparison

Compare SPRO & QXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

SELL

Current Price

$1.10

Market Cap

67.0M

Sector

Health Care

ML Signal

SELL

Logo Quantum X Labs Inc. Common Stock

QXL

Quantum X Labs Inc. Common Stock

SELL

Current Price

$4.41

Market Cap

75.6M

Sector

Technology

ML Signal

SELL

Company Overview

Basic Information
Metric
SPRO
QXL
Founded
2013
N/A
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
67.0M
75.6M
IPO Year
2017
2015

Fundamental Metrics

Financial Performance
Metric
SPRO
QXL
Price
$1.10
$4.41
Analyst Decision
Buy
Analyst Count
2
0
Target Price
★ $5.00
N/A
AVG Volume (30 Days)
★ 839.8K
57.2K
Earning Date
11-12-2026
08-18-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 111.81
N/A
EPS
N/A
★ 0.10
Revenue
★ $66,802,000.00
$26,941,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$38.79
Revenue Growth
★ 39.24
N/A
52 Week Low
$1.08
$3.70
52 Week High
$3.08
$7.70

Technical Indicators

Market Signals
Indicator
SPRO
QXL
Relative Strength Index (RSI) 41.51 45.43
Support Level $1.10 $4.13
Resistance Level $1.28 $5.18
Average True Range (ATR) 0.06 0.40
MACD -0.01 -0.04
Stochastic Oscillator 2.50 36.88

Price Performance

Historical Comparison
SPRO
QXL

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About QXL Quantum X Labs Inc. Common Stock

Quantum X Labs Inc is an Israel-based multi-disciplinary quantum technology company focused on the research, development, and commercialization of quantum technologies and intellectual property. The company operates across a broad range of domains, including quantum computing, quantum sensing, navigation systems, atomic clocks, and quantum algorithms, with applications spanning defense, aerospace, transportation, cybersecurity, and life sciences.

Share on Social Networks: